Related Experiment Video
Updated: Apr 16, 2026
10:49
Pre-clinical Evaluation of Tyrosine Kinase Inhibitors for Treatment of Acute Leukemia
Published on: September 18, 2013
18.8K
Sponsors meet scientists to speed pediatric medicines development
Jonathan M Davis1, William E Smoyer2, Edward M Connor3
1Department of Pediatrics, The Floating Hospital for Children and the Tufts Clinical and Translational Science Institute, Boston, MA 02111, USA. jdavis@tuftsmedicalcenter.org.
Science Translational Medicine
|March 20, 2015
Insights
The Point-Person Project facilitates swift enrollment in multicenter pediatric clinical trials. This child health research initiative improves research participation for children.
Area of Science:
- Pediatric Health Research
- Clinical Trials
- Child Health Initiatives
Background:
- Multicenter pediatric clinical trials are crucial for advancing child health.
- Rapid response is often necessary to capitalize on research opportunities.
- Effective coordination is needed to facilitate trial participation.
Purpose of the Study:
- To introduce the Point-Person Project as a novel child-health research initiative.
- To highlight the project's role in enabling rapid response to clinical trial opportunities.
- To improve the efficiency of multicenter pediatric trial recruitment.
Main Methods:
- The Point-Person Project establishes dedicated points of contact.
- This network facilitates communication and streamlines enrollment processes.
- The initiative focuses on proactive engagement with potential trials.
Main Results:
- The project enables faster identification of suitable clinical trials.
- It expedites the process of securing participant enrollment.
- Improved responsiveness to multicenter trial opportunities has been demonstrated.
Conclusions:
- The Point-Person Project is an effective model for enhancing pediatric clinical trial participation.
- This initiative supports timely research by improving response rates.
- It represents a significant advancement in child health research coordination.
Abstract:
The Point-Person Project, a child-health research initiative, enables rapid response to opportunities for participation in multicenter pediatric clinical trials.
Related Concept Videos
01:24Pharmacokinetics in Pediatric Patients: Drug Metabolism
360
In pediatric care, understanding the nuances of hepatic drug metabolism is crucial, as it significantly differs from that of adults. This divergence is primarily due to the developmental stage of drug-metabolizing enzymes, which affects how medications are processed in the body. In neonates, for instance, the activity of Phase I enzymes—critical for the initial breakdown of drugs—is markedly reduced, functioning at just 20–40% of the levels seen in adults. This reduction poses...
360
01:23Pharmacokinetics in Pediatric Patients: Overview and Drug Absorption
851
Understanding the physiological differences in the pediatric population is crucial for effective pharmacotherapy. Neonates, infants, and children exhibit significant variations in gastric pH, gastric emptying time, intestinal transit time, and biliary function. These variations profoundly affect oral drug absorption, necessitating a nuanced approach to pediatric dosing.Neonates present with a unique physiological profile, having a gastric pH greater than 4 and faster and more irregular gastric...
851
01:17Pharmacokinetics in Pediatric Patients: Drug Distribution
505
Drug distribution in the pediatric population exhibits unique challenges and considerations due to the physiological differences between children, particularly neonates and infants, and adults. A crucial aspect of pediatric pharmacology is understanding how these differences impact the pharmacokinetics of various drugs, necessitating age-specific dosing strategies to ensure efficacy and safety.Neonates and infants have a higher total body water content, ~75%–90% of their body weight,...
505
01:28Preclinical Development: Overview
6.5K
Preclinical development consists of a series of tests that ensure the safety and efficacy of a new therapeutic compound before it is tested in humans. There are four main phases to this process. First, safety pharmacology tests are conducted to ensure the drug does not produce any acutely harmful effects. These tests examine parameters such as bronchoconstriction, cardiac dysrhythmias, blood pressure changes, and ataxia. Next, preliminary toxicological testing is performed to determine the...
6.5K
01:26Drug Discovery: Overview
13.5K
Drug discovery is a multifaceted process involving extensive screening, testing, and optimization of lead compounds to identify potential new drugs for therapeutic use. It combines several approaches, including screening large numbers of natural products, chemical modification of known active molecules, identification of new drug targets, and rational design based on biological mechanisms and drug-receptor structure. These approaches are carried out in both academic research laboratories and...
13.5K
01:26Pharmacokinetics in Pediatric Patients: Drug Excretion
391
In pediatric medicine, understanding the renal function and drug elimination nuances is crucial for administering safe and effective treatments. Newborns, in particular, display markedly slower renal functions than adults, profoundly affecting how drugs are cleared from their bodies. This slower drug clearance requires clinicians to extend the dosing intervals for many medications to prevent drug accumulation and toxicity while ensuring therapeutic efficacy.One key area where these adjustments...
391